Médecine

Paramédical

Autres domaines


S'abonner

Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis - 27/12/17

Doi : 10.1016/j.jaad.2017.06.044 
Julia Dai, MD a, b, Viswanath R. Belum, MD a, Shenhong Wu, MD, PhD c, d, Vincent Sibaud, MD e, Mario E. Lacouture, MD a,
a Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 
b Department of Dermatology, Stanford University, Stanford, California 
c Division of Medical Oncology, Department of Medicine, State University of New York at Stony Brook, Stony Brook, New York 
d Division of Hematology and Oncology, Department of Medicine, Northport Veterans Administration Medical Center, Northport, New York 
e Department of Dermatology, Institut Claudius Regaud-Institut Universitaire du Cancer, Toulouse Oncopole, France 

Correspondence to: Mario. E. Lacouture, MD, Dermatology Service, Memorial Sloan Kettering Cancer Center, 60th Street Outpatient Center, Suite 407, Room 4312, 16 East 60th St, New York, NY 10022.Dermatology ServiceMemorial Sloan Kettering Cancer Center60th Street Outpatient CenterSuite 407Room 4312, 16 East 60th StNew YorkNY10022

Abstract

Background

The discovery of signaling networks that drive oncogenic processes has led to the development of targeted anticancer agents. The burden of pigmentary adverse events from these drugs is unknown.

Objective

To conduct a systematic review and meta-analysis of published clinical trials and determine the incidence and risk of development of targeted therapy–induced pigmentary changes.

Methods

A comprehensive search was conducted to identify studies reporting targeted therapy–induced pigmentary changes. The incidence and relative risk were calculated. Case reports and series were reviewed to understand clinical characteristics.

Results

A total of 8052 patients from 36 clinical trials were included. The calculated overall incidences of targeted cancer therapy–induced all-grade pigmentary changes in the skin and hair were 17.7% (95% confidence interval [CI], 11.9-25.4) and 21.5% (95% CI, 14.9-30.1), respectively. The relative risk of all-grade pigmentary changes of skin and hair were 93.7 (95% CI, 5.86-1497.164) and 20.1 (95% CI, 8.35-48.248). Across 53 case reports/series (N = 75 patients), epidermal growth factor receptor and breakpoint cluster region–abelson inhibitors were the most common offending agents.

Limitations

Potential under-reporting and variability in oncologists reporting these events.

Conclusion

There is a significant risk of development of pigmentary changes during treatment with targeted anticancer therapies. Appropriate counseling and management are critical to minimize psychosocial impairment and deterioration in quality of life.

Le texte complet de cet article est disponible en PDF.

Key words : cabozantinib, depigmentation, dyspigmentation, hyperpigmentation, hypopigmentation, imatinib, ipilimumab, nivolumab, pazopanib, pembrolizumab, pigmentary, repigmentation, sorafenib, sunitinib, vitiligo

Abbreviations used : AE, Bcr-abl, BSA, CI, dpAE, RR, RCT


Plan


 Supported in part by the National Institutes of Health/National Cancer Institute Cancer Center Support Grant P20 CA008748. Drs Lacouture and Belum are supported by the RJR Oncodermatology Fund. Funders and sponsors were not involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.
 Disclosure: Dr Wu has speaking arrangements with Novartis, Bayer-Onyx, Pfizer, and Mediavation. Dr Sibaud has a speaking, consultant, or advisory role with Roche, GlaxoSmithKline, Pierre Fabre, Merck, Bristol-Myers Squibb, Bayer, and Boehringer Ingelheim. Dr Lacouture has a speaking, consultant, or advisory role with Abbvie, Quintiles, Boehringer Ingelheim, AstraZeneca Pharmaceuticals, Legacy Healthcare, Foamix, Adgero Bio Pharmaceuticals, Janssen R&D, Novartis, and Novocure; in addition, he receives research grants from Berg and Bristol-Myers Squibb. Drs Dai and Belum have no conflicts of interest to declare.
 Reprints not available from the authors.


© 2017  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 77 - N° 5

P. 902 - novembre 2017 Retour au numéro
Article précédent Article précédent
  • Cancer risks and survival in patients with multiple primary melanomas: Association with family history of melanoma and germline CDKN2A mutation status
  • Hildur Helgadottir, Rainer Tuominen, Håkan Olsson, Johan Hansson, Veronica Höiom
| Article suivant Article suivant
  • Aesthetic outcome and complications of simple interrupted versus running subcuticular sutures in facial surgery: A randomized controlled trial
  • Xiaomeng Liu, Patty J. Nelemans, Lisa D.S. Frenk, Helma Sengers, Stephania M.H. Tuinder, Peter M. Steijlen, Klara Mosterd, Nicole W.J. Kelleners-Smeets

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

;

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.